PARIS, May 31, 2016 /PRNewswire/ --
At this 52nd annual meeting of the world's most important oncology conference, Gustave Roussy will confirm its leading role in the development of three therapeutic strategies that are changing practice and transforming patient treatment. Immunotherapy, which is extending its application to new conditions, and precision medicine are becoming routine therapeutic options. This 2016 meeting will also be noteworthy for throwing new light on the optimisation of existing treatments, as reflected by the presentation in plenary session of childhood neuroblastoma treatment, for which Dr. Dominique Valteau-Couannet, Head of the Gustave Roussy Paediatric Oncology Department, will be a discussant.
To view the Multimedia News Release, please click: http://www.multivu.com/players/uk/7849451-gustave-roussy-at-asco-2016/
This year, Gustave Roussy medical researchers will be revealing their work in a total of 75 presentations. The ASCO Scientific Committee has selected 21 oral communications, 6 of which will be delivered by doctors from the Institute; 11 poster-discussions, 6 of which are to be presented by Gustave Roussy researchers; and 42 posters and 1 educational session authored by doctor researchers from the Institute. Gustave Roussy is the sponsor of four clinical trials, the results of which will be communicated during the conference.
To discover the major part of Gustave Roussy's research at ASCO 2016, click on the link http://www.gustaveroussy.fr/en/asco2016
About Gustave Roussy
Gustave Roussy is the leading Cancer Centre in Europe. It is a centre where all the skills in cancer care are focused on the patient. It comprises 3,000 professional staff who are engaged in care, research and teaching.
SOURCE Gustave Roussy